Neurosurgical follow-up and treatment of a series of 26 WHO grade III meningiomas

J Clin Neurosci. 2021 Sep:91:219-225. doi: 10.1016/j.jocn.2021.06.047. Epub 2021 Jul 16.

Abstract

Meningiomas are the most common primary intracranial tumors. They have three pathologic grades. Surgical resection aiming Simpson I resection is the standard treatment for meningiomas. Radiotherapy and Gamma Knife radiosurgery are the main adjuvant and salvage treatments. Chemotherapy has limited use. Grade II, and III meningiomas have a higher recurrence rate, and adjuvant radiotherapy is usually the standard treatment for grade III meningiomas. In this paper, we analyzed our meningioma series of 1401 patients and presented the treatment and follow-up results of 26 grade III meningioma cases. Median follow-up of grade III meningiomas was 40.5 (range, 1-154) months. The mean age of patients was 51.7 ± 15.7 years; 12 of them were female and 14 were male (female/male ratio = 0.9). The median progression-free survival (PFS) of them was 22 months, and overall survival (OS) was 62 months. Meningiomas with gross total resection (GTR), non-skull base meningiomas, and primary grade III meningiomas had longer PFS, while meningiomas with GTR, non-skull base meningiomas, and primary meningiomas had longer OS with a statistical significance.

Keywords: Anaplastic meningiomas; Grade III meningiomas; Meningiomas; Papillary meningiomas; Rhabdoid meningiomas.

MeSH terms

  • Adult
  • Aged
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Meningeal Neoplasms* / surgery
  • Meningioma* / surgery
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Retrospective Studies
  • Treatment Outcome
  • World Health Organization